Cu-64-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy
Rodney J Hicks, Price Jackson, Grace Kong, Robert E Ware, Michael S Hofman, David A Pattison, Timothy A Akhurst, Elizabeth Drummond, Peter Roselt, Jason Callahan, Roger Price, Charmaine M Jeffery, Emily Hong, Wayne Noonan, Alan Herschtal, Lauren J Hicks, Amos Hedt, Matthew Harris, Brett M Paterson, Paul S Donnelly
Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2019
Related Projects (1)
Awarded by National Health and Medical Research Council Practitioner Fellowship
This study was funded by Clarity Pharmaceuticals. Rodney Hicks is the recipient of a National Health and Medical Research Council Practitioner Fellowship (APP1108050), which supported this work. Amos Hedt and Matthew Harris are employed by Clarity Pharmaceuticals, the licensee of the intellectual property for SARTATE. Charmaine Jeffery has Clarity Pharmaceuticals share options. Paul Donnelly and Brett Paterson are inventors of, and hold intellectual property in, this area of research, which has been licensed from the University of Melbourne to Clarity Pharmaceuticals. Brett Paterson and Paul Donnelly possess share options in Clarity Pharmaceuticals. Paul Donnelly serves on the Scientific Advisory Board of Clarity Pharmaceuticals. Unrelated to this project, Rodney Hicks has share options in Telix Radiopharmaceuticals that are held on behalf of the Peter MacCallum Cancer Centre. No other potential conflict of interest relevant to this article was reported.